Accessibility Menu
Gilead Sciences logo

Gilead Sciences

(NASDAQ) GILD

Current Price$134.33
Market Cap$166.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+30,818%
5 Year+135%
1 Year+27%
1 Month+7%
Gilead Sciences last closing stock price
MetricPriceDate
Last closeUSD 134.282026-07-17
Gilead Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.43%USD 129.832026-07-10
1 month+7.04%USD 125.452026-06-17
3 month-1.8%USD 136.742026-04-17
Year to date+10.75%USD 121.252025-12-31
1 year+26.63%USD 106.042025-07-17
3 year+89.47%USD 70.872023-07-18
5 year+134.83%USD 57.182021-07-16
Since inception+30,818.01%USD 0.431992-01-22

Gilead Sciences Financials at a Glance

Market Cap

$166.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$29.73B

Net Income (TTM)

$9.22B

EPS (TTM)

$7.35

P/E Ratio

18.27

Dividend

$3.22

Beta (Volatility)

0.41 (Low)

Price

$134.33

Volume

232,594

Open

$138.39

Previous Close

$134.33

Daily Range

$134.09 - $140.48

52-Week Range

$107.75 - $157.29

Estimated Earnings Date

Aug 6, 2026

GILD News

Axesome

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

James HalleyJul 12, 2026
A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026
DNA with a section separated from the main part.

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

Keith SpeightsMay 11, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

How to Invest in iShares Biotechnology ETF (IBB)

Tony DongFeb 25, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in VanEck Biotech ETF (BBH)

Tony DongFeb 25, 2026
Doctor with patient talking

Should You Buy Gilead Sciences Before Feb. 10?

Prosper Junior BakinyFeb 9, 2026
drug development pharmaceutical pharma research researchers doctors

How to Buy Gilead Sciences Stock (GILD)

Matt DiLalloDec 31, 2025
Person checking medicine on a shelf in a pharmacy

Why Gilead Sciences Stock Slipped Today

Eric VolkmanJul 28, 2025
Page 1

GILD: Motley Fool Moneyball Superscore

74

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Gilead Sciences

Gilead Sciences, Inc. is a prominent player in the biopharmaceutical industry, focusing on discovering, developing, and commercializing innovative therapies. The company's strong foothold in HIV and oncology forms the backbone of its business strategy. With a clear emphasis on expanding its product portfolio through strategic acquisitions and partnerships, Gilead aims to deliver groundbreaking treatments in high-demand areas, including cell therapy and HIV.

Products and Services

HIV treatment: Gilead offers a range of antiretroviral therapies for managing HIV infections.

Oncology: Products like Trodelvy are in place to address cancer treatment needs.

Cell therapy: Innovative therapies targeting specific diseases through cellular manipulation.

Research and development: Focused on creating new therapeutic candidates across various conditions.

What Makes Gilead Sciences, Inc. Special

Gilead is distinguished by its robust product pipeline in HIV and active exploration of new therapeutic areas. The company's strategic acquisitions and partnerships boost its capability to deliver critical treatments and enter new markets. Its financial health supports sustained investments in research and development, key to its competitive edge in biotech innovation.

Five Things You Need to Know

Gilead is a leader in HIV treatment with a diverse portfolio of antiretroviral products.

The company's strategic acquisitions, like CymaBay Therapeutics, enhance its product and market diversification.

Gilead is investing heavily in oncology and cell therapy, targeting significant unmet medical needs.

Strong financial performance enables sustained spending in research and innovation.

Potential regulatory challenges could impact the exclusivity of its key HIV products.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17,000

CEO

Daniel P. O'Day, MBA

Website

www.gilead.com

Headquarters

Foster City, CA 94404, US

GILD Financials

Key Financial Metrics (TTM)

Gross Margin

79.35%

Operating Margin

38.26%

Net Income Margin

30.99%

Return on Equity

42.16%

Return on Capital

24.74%

Return on Assets

16.38%

Earnings Yield

5.47%

Dividend Yield

2.40%

Payout Ratio

43.76%

Stock Overview

Market Cap

$166.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.24B

Volume

232.59K

Avg. Volume

7.52M

Financials (TTM)

Gross Profit

$23.60B

Operating Income

$11.38B

EBITDA

$14.02B

Operating Cash Flow

$10.81B

Capital Expenditure

-$576.00M

Free Cash Flow

$10.23B

Cash & ST Invst.

$9.82B

Total Debt

$22.17B

Gilead Sciences Performance Analysis

Gilead Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 27,085,000,000-1.0%
20232023-12-31USD 27,058,000,000-0.1%
20242024-12-31USD 28,727,000,0006.2%
20252025-12-31USD 29,448,000,0002.5%
Gilead Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-306.2%
Q32025-09-309.7%
Q42025-12-312.0%
Q12026-03-31-12.2%
Gilead Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.64-26.2%
20232023-12-31USD 4.5023.8%
20242024-12-31USD 0.38-91.5%
20252025-12-31USD 6.781672.8%
Gilead Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3050.0%
Q32025-09-3055.8%
Q42025-12-31-28.4%
Q12026-03-31-7.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.96B

+4.4%

Gross Profit

$5.52B

+7.6%

Gross Margin

79.24%

N/A

Market Cap

$166.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.81M

N/A

Employees

17,000

N/A

Net Income

$2.02B

+53.7%

EBITDA

$3.04B

+16.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.82B

+23.9%

Total Debt

$22.17B

-11.1%

Accounts Receivable

$4.74B

+8.0%

Inventory

$1.91B

+8.8%

Long Term Debt

$20.86B

-5.8%

Short Term Debt

$1.31B

-53.2%

Return on Assets

16.38%

N/A

Return on Invested Capital

24.30%

N/A

Free Cash Flow

$2.43B

+46.8%

Operating Cash Flow

$2.54B

+44.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DHRDanaher Corporation
$203.83-0.58%
PFEPfizer Inc.
$25.05-0.36%
AMGNAmgen Inc.
$366.29-1.42%
BMYBristol-Myers Squibb Company
$60.74+0.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%

Questions About GILD

What is the current price of Gilead Sciences?

Gilead Sciences is trading at $134.33 per share.

What is the 52-week range for Gilead Sciences?

Over the past 52 weeks, Gilead Sciences has traded between $107.75 and $157.29.

How much debt does Gilead Sciences have?

As of the most recent reporting period, Gilead Sciences reported total debt of $22.17B.

How much cash does Gilead Sciences have on hand?

Gilead Sciences reported $7.63B in cash and cash equivalents in its most recent financial results.

What is Gilead Sciences’s dividend yield?

Gilead Sciences currently has a dividend yield of 2.40%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services